A chemical linker synthesized with an alpha-1,3-gal-gal bond on one end and a DNA aptamer devised to bind specifically to the strain of influenza you have on the other end will link anti-alpha-Gal antibodies to the influenza virus and presto! Source: Internet
According to the FDA, the antibodies against the novel coronavirus are 'generally detectable in blood several days after initial infection.' Source: Internet
Additionally, red blood cell surface antigens other than A, B and Rh D, might cause adverse reactions and sensitization, if they can bind to the corresponding antibodies to generate an immune response. Source: Internet
Actually, this time is was an emergency authorization by the FDA for convalescent plasma therapy — basically an infusion of antibodies from a person who has recovered from COVID into a person with an active infection. Source: Internet
A French study has shown even people with mild symptoms of the coronavirus develop antibodies, raising hope of immunity. Source: Internet
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Source: Internet